Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Weatherald

Showing results (1-10 of 154) with videos related to

Pageof 16
Sort By:
Respirology (Carlton, Vic.)|April 3, 2020
The 'great wait' for diagnosis in pulmonary arterial hypertensionJason Weatherald, Marc Humbert
Frontiers in Physiology|August 28, 2020
Pulmonary Vascular Disease and Cardiopulmonary Exercise TestingPierantonio Laveneziana, Jason Weatherald
The European Respiratory Journal|May 7, 2025
Pulmonary arterial hypertension and targeting pulmonary vascular remodelling: are we there yet?James Lordan, Jason Weatherald
Methodist Debakey Cardiovascular Journal|July 30, 2021
Management of Pulmonary Hypertension Due to Chronic Lung DiseaseJordan Sugarman, Jason Weatherald
Chest|March 9, 2024
Rebuttal From Drs Weatherald and SitbonJason Weatherald, Olivier Sitbon
Chest|March 9, 2024
POINT: Should the Use of Upfront Triple Combination Therapy Be Standard of Care in Pulmonary Arterial Hypertension? YesJason Weatherald, Olivier Sitbon
Respirology (Carlton, Vic.)|November 1, 2022
PDE5 to keep them alive: The use of phosphodiesterase type-5 inhibitors in severe pulmonary hypertension associated with interstitial lung diseaseJason Weatherald, Marc Humbert
The European Respiratory Journal|July 6, 2018
Right heart catheterisation is still a fundamental part of the follow-up assessment of pulmonary arterial hypertensionMarc Humbert, Jason Weatherald
Lancet (London, England)|March 25, 2023
Ordinal outcomes add value to clinical trials - Authors' replyJason Weatherald, Marc Humbert
The American Journal of Medicine|May 6, 2008
Pseudocyanosis: drug-induced skin hyperpigmentation can mimic cyanosisJason Weatherald, Thomas J Marrie
Pageof 16

Showing results (1-10 of 154) with videos related to

Sort By:
Pageof 16
Respirology (Carlton, Vic.)|April 3, 2020
The 'great wait' for diagnosis in pulmonary arterial hypertensionJason Weatherald, Marc Humbert
Frontiers in Physiology|August 28, 2020
Pulmonary Vascular Disease and Cardiopulmonary Exercise TestingPierantonio Laveneziana, Jason Weatherald
The European Respiratory Journal|May 7, 2025
Pulmonary arterial hypertension and targeting pulmonary vascular remodelling: are we there yet?James Lordan, Jason Weatherald
Methodist Debakey Cardiovascular Journal|July 30, 2021
Management of Pulmonary Hypertension Due to Chronic Lung DiseaseJordan Sugarman, Jason Weatherald
Chest|March 9, 2024
Rebuttal From Drs Weatherald and SitbonJason Weatherald, Olivier Sitbon
Chest|March 9, 2024
POINT: Should the Use of Upfront Triple Combination Therapy Be Standard of Care in Pulmonary Arterial Hypertension? YesJason Weatherald, Olivier Sitbon
Respirology (Carlton, Vic.)|November 1, 2022
PDE5 to keep them alive: The use of phosphodiesterase type-5 inhibitors in severe pulmonary hypertension associated with interstitial lung diseaseJason Weatherald, Marc Humbert
The European Respiratory Journal|July 6, 2018
Right heart catheterisation is still a fundamental part of the follow-up assessment of pulmonary arterial hypertensionMarc Humbert, Jason Weatherald
Lancet (London, England)|March 25, 2023
Ordinal outcomes add value to clinical trials - Authors' replyJason Weatherald, Marc Humbert
The American Journal of Medicine|May 6, 2008
Pseudocyanosis: drug-induced skin hyperpigmentation can mimic cyanosisJason Weatherald, Thomas J Marrie
Pageof 16